Easton Pharmaceuticals Inc (EAPH) Stock Price, Trades & News

Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.

Financial Strength

	Name	Current	Vs Industry		Vs History

Growth Rank

	Name	Current	Vs Industry		Vs History

Momentum Rank

	Name	Current	Vs Industry		Vs History
	9-Day RSI	100
	14-Day RSI	100
	3-1 Month Momentum %	100
	6-1 Month Momentum %	100
	12-1 Month Momentum %	100

Liquidity Ratio

	Name	Current	Vs Industry		Vs History

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History

Profitability Rank

	Name	Current	Vs Industry		Vs History

GF Value Rank

2/10

Name	Current	Vs Industry	Vs History
PE Ratio	N/A	N/A	N/A
PE Ratio without NRI	N/A	N/A	N/A
FCF Yield %	-2709100

GF Value™

EAPH

Warning Signs

Warning! GuruFocus detected issues with EAPH. Try a 7-Day Free Trial to check it out.

Easton Pharmaceuticals Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Easton Pharmaceuticals Inc Stock Events

Financials Calendars

	Event	Date	Price ($)
	0.000333:1 Stock Split	2009-04-30	0.90 (-40.00%)

Show

Entries

Guru Commentaries on OTCPK:EAPH

No articles.

Press Release

	Subject	Date
	Easton Announces That it Is Moving its Corporate Office After the Purchase of its Food Processing Company Specializing in Baked Goods and the Launch of its New Website	2019-04-30
	Easton Closes Purchase of Food Processing Company Specializing in Baked Goods with Projected Revenues Over $20,000,000 per Year and Positioned to Enter the Cannabis Edibles Market	2019-04-24
	Easton Provides Update on the Closing of its Agreement To Acquire Commercial Bakery	2019-04-12
	Easton Announces Status Update On Its $2,600,000 Framing Contract To Construct 150 Homes, Including Update on Its Development Project in Cobourg, Ontario	2019-04-11
	Easton Signs LOI with Licensed Producer of Cannabis to Expand its Operations and Participate in its Cannabis Edibles Division	2019-04-11
	Easton Announces Signing of Joint Venture Agreement for the Purchase and Development of 9 Townhomes with Revenue in Excess of $4 Million and Provides Update on its Framing Contract with Revenues of $770K for Q1	2019-04-11
	Easton Provides Update on the Closing of its Agreement To Acquire Commercial Bakery with Projected Revenues Over $20,000,000 per Year and Positioned to Enter the Cannabis Edibles Market	2019-04-11
	Easton Commences Cannabis Edibles Division and Announces Updates on Its Filing for the Period Ended December 31, 2018	2019-04-11
	Easton Announces Filing of Its Financial Statements for the Year Ended December 31, 2018 with a Revenue Increase of 145% Over 2017 and Provides General Business Update	2019-04-11

10/Page

Articles on Easton Pharmaceuticals Inc

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.